{"id":55583,"date":"2023-04-06T14:03:18","date_gmt":"2023-04-06T12:03:18","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/"},"modified":"2023-04-06T14:03:18","modified_gmt":"2023-04-06T12:03:18","slug":"affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/","title":{"rendered":"Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023"},"content":{"rendered":"<div>\n<p>BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;<a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.affinittx.com%2F&amp;esheet=53376448&amp;newsitemid=20230406005127&amp;lan=en-US&amp;anchor=Affini-T+Therapeutics%2C+Inc&amp;index=1&amp;md5=83451720264688f6cdbf06dd6ac4e3a0\" rel=\"nofollow noopener\" shape=\"rect\">Affini-T Therapeutics, Inc<\/a>., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that its Chief Scientific Officer, Lo\u00efc Vincent, Ph.D., will present data from the Company\u2019s oncogenic driver program targeting KRAS G12D, at this year\u2019s American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, Florida, taking place April 14<sup>th<\/sup> \u2013 19<sup>th<\/sup>.<\/p>\n<p><a href=\"https:\/\/mms.businesswire.com\/media\/20230406005127\/en\/1396868\/5\/Affini-T_Therapeutics_logo.jpg\"><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20230406005127\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg\"><\/a><\/p>\n<p>\nOral presentation details are as follows:<\/p>\n<ul class=\"bwlistdisc\">\n<li>\n<b><span class=\"bwuline\">Session MS.CL07.01 &#8211; Immunotherapy<\/span><\/b><span class=\"bwuline\">: Sunday, April 16<sup>th<\/sup> from 3:52 pm &#8211; 4:07 pm ET<\/span>: Preclinical development of safe and effective T cell receptors specific for mutant KRAS G12D peptide<\/li>\n<\/ul>\n<p>\n<b>About Affini-T Therapeutics<\/b><\/p>\n<p>\nAffini-T is unlocking the power of T cells and targeting core oncogenic drivers to develop potentially curative therapies for solid tumor cancers. Our differentiated cell therapy platforms harness state-of-the-art engineering, synthetic biology and gene editing capabilities to target even the most devastating cancer-driving mutations, beginning with KRAS. We leverage these tools to optimize T cell functions and rewrite the rules of the solid tumor microenvironment, enabling the potential for sustained clinical outcomes in patients. Building on the world-class innovation inherent in our leadership team, founders and technologies, we are powered to develop transformational medicines that last. Follow us on <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.linkedin.com%2Fcompany%2Faffini-t-therapeutics%2F&amp;esheet=53376448&amp;newsitemid=20230406005127&amp;lan=en-US&amp;anchor=LinkedIn&amp;index=2&amp;md5=7f44f3497b79f809d691a97fe1f985c9\" rel=\"nofollow noopener\" shape=\"rect\">LinkedIn<\/a> and <a target=\"_blank\" href=\"https:\/\/cts.businesswire.com\/ct\/CT?id=smartlink&amp;url=https%3A%2F%2Ftwitter.com%2Faffinit_tx&amp;esheet=53376448&amp;newsitemid=20230406005127&amp;lan=en-US&amp;anchor=Twitter&amp;index=3&amp;md5=05b4d3dfb698fa23f9994832e20f3537\" rel=\"nofollow noopener\" shape=\"rect\">Twitter<\/a>.<\/p>\n<p> <b>Contacts<\/b> <\/p>\n<p>\n<b>Media Contacts<\/b><br \/>Danielle Cantey<br \/>\n<br \/>Evoke Canale<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;i&#x6c;&#x74;&#111;:&#x44;&#x61;&#110;i&#x65;&#108;l&#x65;&#x2e;&#67;a&#x6e;&#x74;&#101;y&#x40;&#101;&#118;&#x6f;&#x6b;&#101;g&#x72;&#x6f;&#117;p&#x2e;&#99;&#111;m\" rel=\"nofollow noopener\" shape=\"rect\">&#x44;&#97;n&#x69;&#x65;&#108;l&#x65;&#x2e;&#67;a&#x6e;&#x74;&#101;y&#x40;&#x65;&#118;o&#x6b;&#101;&#103;r&#x6f;&#117;p&#x2e;&#x63;&#111;m<\/a><br \/>619-826-4657<\/p>\n<p>\n<b>Investor Contact<br \/>\n<br \/><\/b>Ailsa Dalgliesh, PhD<br \/>\n<br \/><a target=\"_blank\" href=\"&#x6d;&#97;&#x69;&#108;t&#x6f;&#58;a&#x69;&#108;&#x73;&#x61;&#64;&#x61;&#102;f&#x69;&#110;&#x69;&#x74;t&#x78;&#46;c&#x6f;&#109;\" rel=\"nofollow noopener\" shape=\"rect\">a&#105;&#108;&#x73;&#x61;&#64;a&#102;&#102;&#x69;&#x6e;it&#116;&#120;&#x2e;&#x63;om<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that its Chief Scientific Officer, Lo\u00efc Vincent, Ph.D., will present data from the Company\u2019s oncogenic driver program targeting KRAS G12D, at this year\u2019s American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, &#8230; <span class=\"more\"><a class=\"more-link\" href=\"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/\">[Read more&#8230;]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-55583","6":"format-standard","7":"category-industry"},"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that its Chief Scientific Officer, Lo\u00efc Vincent, Ph.D., will present data from the Company\u2019s oncogenic driver program targeting KRAS G12D, at this year\u2019s American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-06T12:03:18+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230406005127\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023\",\"datePublished\":\"2023-04-06T12:03:18+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/\"},\"wordCount\":251,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230406005127\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/\",\"name\":\"Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230406005127\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\",\"datePublished\":\"2023-04-06T12:03:18+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230406005127\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230406005127\\\/en\\\/1396868\\\/21\\\/Affini-T_Therapeutics_logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/","og_locale":"en_US","og_type":"article","og_title":"Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Pharma Trend","og_description":"BOSTON &amp; SEATTLE&#8211;(BUSINESS WIRE)&#8211;Affini-T Therapeutics, Inc., a biotechnology company unlocking the power of T cells against oncogenic driver mutations, today announced that its Chief Scientific Officer, Lo\u00efc Vincent, Ph.D., will present data from the Company\u2019s oncogenic driver program targeting KRAS G12D, at this year\u2019s American Association for Cancer Research (AACR) Annual Meeting 2023 in Orlando, ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/","og_site_name":"Pharma Trend","article_published_time":"2023-04-06T12:03:18+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230406005127\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023","datePublished":"2023-04-06T12:03:18+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/"},"wordCount":251,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230406005127\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/","url":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/","name":"Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023 - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230406005127\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","datePublished":"2023-04-06T12:03:18+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230406005127\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230406005127\/en\/1396868\/21\/Affini-T_Therapeutics_logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/affini-t-therapeutics-to-present-preclinical-data-from-its-oncogenic-driver-program-targeting-kras-at-the-american-association-for-cancer-research-aacr-annual-meeting-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"Affini-T Therapeutics to Present Preclinical Data from its Oncogenic Driver Program Targeting KRAS at the American Association for Cancer Research (AACR) Annual Meeting 2023"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55583","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=55583"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/55583\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=55583"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=55583"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=55583"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}